Atorvastatin associated with modest but clinically apparent improvement in RA symptoms
Investigators in the Trial of Atorvastatin in Rheumatoid Arthritis (TARA) assessed whether statins would reduce inflammatory symptoms in patients with RA. Patients with RA (N=116) were randomized in the double-blind, placebo-controlled trial to receive 40 mg of atorvastatin or placebo in addition to their current disease-modifying antirheumatic drug (DMARD) therapy.
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.